Daniel Coriat on Colombia’s standing in the BCI report

Posted by:

As part of the coverage of the event celebrating 60 years of Afidro where industry, government, patient groups and other stakeholders gathered in Bogota on March 2018, a leading 24-hour news channels in Colombia interviews Pugatch Consilium’s Daniel Coriat on Colombia’s standing in the BCI report. Daniel explains how policies not geared to promote innovation hurt Colombia’s international standing and competitiveness in attracting foreign direct investment.

Listen to the interview

Continue Reading →
0

Towards a Sustainable European Market for Off-Patent Biologics

Posted by:

Professor Meir Pugatch spoke yesterday at the event: “Building a sustainable Policy Framework for Biologics and Biosimilar Medicines in Europe”, which took place at the European Parliament, and included members from the European Commission and organizations such as Medicines for Europe, ESMO and EPF. Professor Pugatch presented the findings of a new study by Pugatch Consilium, commissioned by the European Federation of Pharmaceutical Industries and Associations (EFPIA).

With 38 biosimilar medicines approved and marketed and hundreds of clinical trials on ...

Continue Reading →
0

Why IP Incentives Matter for Life Sciences Innovation – In Europe and Beyond

Posted by:

Why IP incentives matter for life sciences innovation – In Europe and Beyond

Pugatch Consilium is today releasing a new report – A Critical Incentive – Not a Barrier! How IP incentives spur biopharmaceutical innovation and the creation of new health technologies.

This report examines the importance of IP based incentives to biopharmaceutical innovation and the development of new medicines and medical technologies.

This analysis could not be more timely. In Europe, for example, the EU Commission is seriously considering ways to ...

Continue Reading →
0

BCI 2017 Latin America Report and Results Released

Posted by:

Pugatch Consilium unveiled at the Financial Times Latin America Healthcare & Life Sciences Summit in Sao Paulo Brazil the 2017 Biopharmaceutical Competitiveness & Investment (BCI) Latin America Special Report. This Report is derived from the main 2017 BCI Survey, a global executive opinion survey and index that measures the relative attractiveness of economies to investment from biopharmaceutical research-based companies.

The Report deep-dives into ten Latin American countries: Argentina, Brazil, Chile, Colombia, Costa Rica, Dominican Republic, Ecuador, Mexico, Panama and Peru. ...

Continue Reading →
0

Debunking the IP and Access to Medicines Myth Once and For All

Posted by:

Pugatch Consilium is today releasing the report Unlocking Global Health Strengthening Availability of Essential Medicines by Enhancing Healthcare Financing and Reducing Supply Chain Costs.

This report examines a common misperception in the international community: that patents and IP incentives block access to medicines.

 

An age-old debate: Patents and access

Discussions over the impact – positive or negative; rarely neutral – that IP rights have had and continue to have on the creation and dissemination of new ideas and commercial products is ...

Continue Reading →
0

To SPC or not to SPC…

Posted by:

Does the EU Commission really think weakening IP incentives for biopharmaceutical innovation in Europe is going to create more jobs and economic activity?

by Dr David Torstensson, Partner, Pugatch Consilium

As an industry the research-based biopharmaceutical sector is one of Europe’s biggest success stories. Companies like Novartis, Roche, Sanofi Aventis, Novo Nordisk, AstraZeneca and GSK are some of the largest, most innovative and successful research-based biopharmaceutical companies in the world. Not only do these companies have a long track record of producing ...

Continue Reading →
0

BCI 2017 Report and Results Released

Posted by:

Pugatch Consilium has released the 2017 Biopharmaceutical Competitiveness & Investment (BCI) Survey. An executive opinion survey, in 2017 the BCI polled business leaders and local general managers from the biopharmaceutical industry about the investment environment in 31 markets. The results are available in the linked report below.

 

The headline results of the 2017 BCI Survey include:

 

  • The policy environment matters a great deal for biopharmaceutical investment decisions. Economies with policies supporting biopharmaceutical innovation and investment are much more likely to actually secure ...
Continue Reading →
0

Unintended Consequences

Posted by:

Pugatch Consilium releases new study on the negative economic consequences of an SPC export exemption in Europe

Today Pugatch Consilium releases UNINTENDED CONSEQUENCES: How introducing a manufacturing and export exemption to supplementary protection certificates would weaken global standards of IP protection and result in direct losses to Europe’s research-based biopharmaceutical industry.

The study (which is also available via the Social Science Research Network, SSRN) models the economic impact an SPC manufacturing and export exemption would have on the European and global research-based ...

Continue Reading →
0

Preliminary BCI 2017 Results and New Impact Analysis Published

Posted by:

In a world of global investment flows, securing a larger portion of the $150 billion invested per year by the research-based biopharmaceutical industry is anyone’s game. The 2017 results of the annual Biopharmaceutical Competitiveness & Investment (BCI) Survey, previewed at the International BIO Convention in San Diego in June, reveal that biopharmaceutical competitiveness turns on the policy conditions that countries decide to put in place.

 

A new blog post by Prof Meir Pugatch on PhRMA’s The Catalyst discusses these results and ...

Continue Reading →
0
Page 1 of 14 12345...»